Skip to main content

Advertisement

Table 1 Statistical analysis of delta changes of cholesterol and apolipoprotein subclasses in liraglutide- and placebo-treated individuals

From: Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial

Cholesterol Placebo Liraglutide P1 P2
Visit 1 Visit 6 Delta changes Visit 1 Visit 6 Delta changes
Total chol. 3.51 ± 0.78 3.69 ± 0.82 0.18 ± 0.09 3.44 ± 0.77 3.28 ± 0.73 − 0.17 ± 0.12 0.01 0.008
Free chol. 1.08 ± 0.24 1.13 ± 0.25 0.05 ± 0.02 1.06 ± 0.24 1.01 ± 0.23 − 0.05 ± 0.03 0.01 0.01
Remnant chol. 1.14 ± 0.26 1.24 ± 0.28 0.1 ± 0.04 1.11 ± 0.25 1.09 ± 0.24 − 0.03 ± 0.04 0.01 0.02
VLDL chol. 0.58 ± 0.13 0.64 ± 0.14 0.07 ± 0.02 0.55 ± 0.12 0.56 ± 0.13 0.01 ± 0.02 0.05 0.16
LDL chol. 1.35 ± 0.3 1.39 ± 0.31 − 0.04 ± 0.11 1.34 ± 0.3 1.24 ± 0.28 − 0.09 ± 0.06 0.62 0.57
HDL chol. 1.01 ± 0.22 1 ± 0.22 − 0.005 ± 0.02 0.99 ± 0.22 0.95 ± 0.21 − 0.05 ± 0.03 0.22 0.06
HDL2 chol. 0.55 ± 0.12 0.51 ± 0.11 − 0.06 ± 0.05 0.53 ± 0.12 0.5 ± 0.11 − 0.03 ± 0.02 0.61 0.91
HDL3-C (× 10−2) 46.2 ± 10.3 46.2 ± 10.3 0.02 ± 0.3 46.2 ± 10.3 44.9 ± 10 − 1.31 ± 0.39 0.01 0.01
Est. Chol. 2.43 ± 0.54 2.5 ± 0.56 − 0.06 ± 0.17 2.38 ± 0.53 2.27 ± 0.51 − 0.12 ± 0.09 0.73 0.72
Serum-TG 1.09 ± 0.24 1.07 ± 0.24 − 0.13 ± 0.11 1 ± 0.22 1.03 ± 0.23 0.02 ± 0.03 0.19 0.32
VLDL-TG 0.73 ± 0.16 0.71 ± 0.16 − 0.09 ± 0.08 0.66 ± 0.15 0.69 ± 0.16 0.03 ± 0.03 0.15 0.24
LDL-TG (× 10−2) 14.8 ± 3.3 14.9 ± 3.32 0.06 ± 0.44 14.1 ± 3.15 13.2 ± 2.96 − 0.87 ± 0.38 0.16 0.12
HDL-TG (× 10−2) 11.2 ± 2.5 11.9 ± 2.66 0.7 ± 0.41 10.7 ± 2.39 10.8 ± 2.41 0.12 ± 0.38 0.29 0.56
TotPG 1.42 ± 0.32 1.47 ± 0.33 0.05 ± 0.04 1.35 ± 0.3 1.34 ± 0.3 − 0.02 ± 0.04 0.22 0.21
PC 1.36 ± 0.3 1.42 ± 0.31 0.06 ± 0.03 1.3 ± 0.29 1.29 ± 0.29 − 0.01 ± 0.04 0.19 0.14
SM 0.43 ± 0.1 0.45 ± 0.1 0.01 ± 0.01 0.43 ± 0.1 0.41 ± 0.09 − 0.02 ± 0.01 0.03 0.01
TotCho 1.79 ± 0.4 1.84 ± 0.41 0.05 ± 0.04 1.73 ± 0.39 1.7 ± 0.38 − 0.03 ± 0.04 0.18 0.12
Apolipoproteins
 ApoA1 (g/L) 1.18 ± 0.26 1.2 ± 0.27 0.02 ± 0.01 1.17 ± 0.26 1.14 ± 0.26 − 0.03 ± 0.02 0.08 0.04
 ApoB (g/L) 0.76 ± 0.17 0.81 ± 0.18 0.04 ± 0.02 0.74 ± 0.17 0.73 ± 0.16 − 0.02 ± 0.02 0.01 0.02
 ApoB/ApoA1 (× 102) 65.3 ± 14.6 67.6 ± 15.2 2.35 ± 1.2 64.4 ± 14.4 64.1 ± 14.3 − 0.29 ± 1.04 0.05 0.21
  1. Values are given in mmol/L. P1—Delta statistics unadjusted. P2—Delta changes adjusted for weight change. Values are reported as mean ± SE. On treatment analysis was performed for all variables. The level of significance was set to p-value < 0.05 after Bonferroni correction. Baseline samples were collected at visit 1, post treatment samples were collected at visit 6
  2. Total chol serum total cholesterol, VLDL-C total cholesterol in VLDL, Remnant chol remnant cholesterol (non-HDL, non-LDL -cholesterol), LDL chol total cholesterol in LDL, HDL chol total cholesterol in HDL, HDL2-C total cholesterol in HDL2, HDL3-C total cholesterol in HDL3, EstC Esterified cholesterol, FreeC free cholesterol, Serum-TG serum total triglycerides, VLDL-TG triglycerides in VLDL, LDL-TG triglycerides in LDL, HDL-TG triglycerides in HDL, TotPG total phosphoglycerides, PC phosphatidylcholine and other cholines, SM sphingomyelins, TotCho total cholines, ApoA1 apolipoprotein A-I, ApoB apolipoprotein B, ApoB/ApoA1 ratio of apolipoprotein B to apolipoprotein A-I